Findx
EnglishEnglish
Dansk Dansk

Chosa Oncology AB stock analysis W5L.DE

CHOSA Oncology AB is a biotechnology company focused on developing precision oncology tools and therapies centred on platinum-based treatments. Its primary product candidates are LiPlaCis®, a liposomal formulation of cisplatin designed to improve delivery and reduce toxicity, and Platin-DRP® (Drug Response Predictor), its companion diagnostic test that predicts patient response to cisplatin or carboplatin chemotherapy. Together, LiPlaCis and Platin-DRP form the "iCIP™" platform.

The company conducts and collaborates on clinical studies in cancers such as lung and breast cancer to validate its diagnostic and therapeutic tools. Platin-DRP® has been validated in multiple independent lung-cancer studies and breast cancer studies, including retrospective analyses assessing carboplatin efficacy in metastatic breast cancer based on Platin-DRP® scores. LiPlaCis®, as a reformulated cisplatin, aims to offer improved tumor targeting via liposomal delivery, which may reduce harmful side effects.

Chosa is headquartered in Lund, Sweden, with operations also rooted in Copenhagen, Denmark. It holds global licensing rights to LiPlaCis® and Platin-DRP®, acquired through its merger with RhoVac and acquisition of Chosa ApS. The company seeks partnerships or sublicensing arrangements for its iCIP™ platform and engages with key opinion leaders in lung, breast, bladder, head and neck cancers to support adoption of its diagnostic technology.

Healthcare · Biotechnology · Biotechnology · Sweden
Quality
Quality
Momentum
Momentum
Strength
Strength
Entry
Entry: N/A
Trend
Trend: N/A
‹
›

Click to see warnings

Neg. values

Log in
‹
›
Years
Lower P/E (Bear)
Sign in to view
Fair Value
Sign in to view
Upper P/E (Bull)
Sign in to view
Analysts
Sign in to view
Price: Financials: Q2 FY2026 / FY2025TTM presentEstimates: UnavailableScored as: Standard companyEvidence: IncompleteDetails

Freshness

  • Price through:
  • Latest annual period: FY2025 (); filed
  • Latest interim period: Q2 FY2026 (); filed
  • TTM period: ; used by: Quality, Strength
  • No future Diluted EPS estimate is available.
  • Target price: Date unknown, Analyst count unknown

Scoring profile

Effective scoring profile: Standard company

Report a suspected classification error

Score evidence

Quality: Unavailable; Not enough evidence; TTM used
Business Momentum: Limited; Limited confidence; TTM not used
Strength: Score calculated; Limited confidence; TTM used
  • Quality score unavailable because too little of the model could be assessed. Missing: Business Development, Cash Conversion, Free Cash Flows, Gross Profitability, Margin Stability.
  • Business Momentum was calculated without one or more required inputs.
  • Limited confidence: 60% of the Business Momentum model could be assessed. Latest surprise, Estimate revisions, Profitability, Revenue could not be assessed because a required input is missing.
  • Limited confidence for Strength by model design: some checks rest on only three or four full fiscal years; diluted EPS stood in for normalized EPS.

Sources and adjustments

Remaining score inputs are provider supplied.

  • Debt to operating cash flow: derived by Findx
  • Net debt to EBITDA: derived by Findx
  • FCF margin: approved fallback

Key stock metrics

Blended P/E  :
P/E (last full year) :
N/A
N/A
Blended EPS  :
EUR N/A
Blended EPS Yield  :
N/A
Dividend Yield :
(Trailing 12 months)
0.00%
Buyback Yield :
(Trailing 12 months)
-36.11%
Market Cap:EUR 3.07 M

Valuation basis

Analyst price target
How this valuation works
Yearly EPS growth  :
( years incl. estimates)
N/A

P/E Values

Upper P/E:
Fair Value P/E  :
Lower P/E:
Market P/E  :
Sign in to view

EPS Estimates

:
N/A
:
N/A
:
N/A

About Chosa Oncology AB

Description, revenue sources, strengths and weaknesses

DESCRIPTION

CHOSA Oncology AB is a biotechnology company focused on developing precision oncology tools and therapies centred on platinum-based treatments. Its primary product candidates are LiPlaCis®, a liposomal formulation of cisplatin designed to improve delivery and reduce toxicity, and Platin-DRP® (Drug Response Predictor), its companion diagnostic test that predicts patient response to cisplatin or carboplatin chemotherapy. Together, LiPlaCis and Platin-DRP form the "iCIP™" platform.

The company conducts and collaborates on clinical studies in cancers such as lung and breast cancer to validate its diagnostic and therapeutic tools. Platin-DRP® has been validated in multiple independent lung-cancer studies and breast cancer studies, including retrospective analyses assessing carboplatin efficacy in metastatic breast cancer based on Platin-DRP® scores. LiPlaCis®, as a reformulated cisplatin, aims to offer improved tumor targeting via liposomal delivery, which may reduce harmful side effects.

Chosa is headquartered in Lund, Sweden, with operations also rooted in Copenhagen, Denmark. It holds global licensing rights to LiPlaCis® and Platin-DRP®, acquired through its merger with RhoVac and acquisition of Chosa ApS. The company seeks partnerships or sublicensing arrangements for its iCIP™ platform and engages with key opinion leaders in lung, breast, bladder, head and neck cancers to support adoption of its diagnostic technology.

ADDITIONAL INFO

It is very important that you understand this

Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.